Tissue | Expression Dynamics | Abbreviation |
Breast | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Breast/ALG8_pca_on_diff_genes.png) | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ALG8_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ALG8_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/ALG8_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ALG8_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064876 | Esophagus | HGIN | protein N-linked glycosylation | 17/2587 | 65/18723 | 6.04e-03 | 4.87e-02 | 17 |
GO:000648714 | Esophagus | ESCC | protein N-linked glycosylation | 51/8552 | 65/18723 | 6.41e-08 | 1.13e-06 | 51 |
GO:00091002 | Esophagus | ESCC | glycoprotein metabolic process | 226/8552 | 387/18723 | 2.64e-07 | 3.94e-06 | 226 |
GO:00181969 | Esophagus | ESCC | peptidyl-asparagine modification | 22/8552 | 24/18723 | 2.82e-06 | 3.21e-05 | 22 |
GO:00700854 | Esophagus | ESCC | glycosylation | 144/8552 | 240/18723 | 5.12e-06 | 5.38e-05 | 144 |
GO:00182799 | Esophagus | ESCC | protein N-linked glycosylation via asparagine | 21/8552 | 23/18723 | 5.69e-06 | 5.90e-05 | 21 |
GO:00064865 | Esophagus | ESCC | protein glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00434135 | Esophagus | ESCC | macromolecule glycosylation | 135/8552 | 226/18723 | 1.36e-05 | 1.24e-04 | 135 |
GO:00091012 | Esophagus | ESCC | glycoprotein biosynthetic process | 181/8552 | 317/18723 | 2.54e-05 | 2.15e-04 | 181 |
GO:00064882 | Esophagus | ESCC | dolichol-linked oligosaccharide biosynthetic process | 14/8552 | 18/18723 | 5.77e-03 | 2.14e-02 | 14 |
GO:00064902 | Esophagus | ESCC | oligosaccharide-lipid intermediate biosynthetic process | 14/8552 | 19/18723 | 1.27e-02 | 4.21e-02 | 14 |
GO:000648711 | Liver | HCC | protein N-linked glycosylation | 48/7958 | 65/18723 | 2.85e-07 | 5.00e-06 | 48 |
GO:001819611 | Liver | HCC | peptidyl-asparagine modification | 21/7958 | 24/18723 | 6.62e-06 | 7.97e-05 | 21 |
GO:001827911 | Liver | HCC | protein N-linked glycosylation via asparagine | 20/7958 | 23/18723 | 1.37e-05 | 1.51e-04 | 20 |
GO:00064862 | Liver | HCC | protein glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00434132 | Liver | HCC | macromolecule glycosylation | 122/7958 | 226/18723 | 3.11e-04 | 2.21e-03 | 122 |
GO:00700852 | Liver | HCC | glycosylation | 128/7958 | 240/18723 | 4.35e-04 | 2.92e-03 | 128 |
GO:0009100 | Liver | HCC | glycoprotein metabolic process | 193/7958 | 387/18723 | 1.89e-03 | 9.62e-03 | 193 |
GO:00064875 | Oral cavity | OSCC | protein N-linked glycosylation | 44/7305 | 65/18723 | 2.63e-06 | 3.26e-05 | 44 |
GO:00181968 | Oral cavity | OSCC | peptidyl-asparagine modification | 20/7305 | 24/18723 | 1.10e-05 | 1.14e-04 | 20 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ALG8 | SNV | Missense_Mutation | novel | c.76N>C | p.Cys26Arg | p.C26R | Q9BVK2 | protein_coding | deleterious(0.01) | benign(0.381) | TCGA-B5-A3FC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALG8 | SNV | Missense_Mutation | novel | c.565G>A | p.Ala189Thr | p.A189T | Q9BVK2 | protein_coding | tolerated(0.06) | possibly_damaging(0.893) | TCGA-D1-A0ZZ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | paclitaxel | SD |
ALG8 | SNV | Missense_Mutation | rs763258107 | c.710N>A | p.Arg237His | p.R237H | Q9BVK2 | protein_coding | tolerated(0.12) | benign(0.219) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALG8 | SNV | Missense_Mutation | rs140716983 | c.1328C>T | p.Ser443Leu | p.S443L | Q9BVK2 | protein_coding | tolerated(0.69) | benign(0.01) | TCGA-D1-A16X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALG8 | SNV | Missense_Mutation | | c.1411N>A | p.Glu471Lys | p.E471K | Q9BVK2 | protein_coding | tolerated(0.3) | benign(0.139) | TCGA-D1-A17F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALG8 | SNV | Missense_Mutation | novel | c.909N>T | p.Leu303Phe | p.L303F | Q9BVK2 | protein_coding | tolerated(0.17) | benign(0.056) | TCGA-EO-A22X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | Complete Response |
ALG8 | SNV | Missense_Mutation | novel | c.523N>T | p.Leu175Phe | p.L175F | Q9BVK2 | protein_coding | tolerated(0.05) | probably_damaging(0.998) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
ALG8 | SNV | Missense_Mutation | novel | c.73N>G | p.Lys25Glu | p.K25E | Q9BVK2 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EY-A1G8-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ALG8 | SNV | Missense_Mutation | novel | c.1381N>G | p.Thr461Ala | p.T461A | Q9BVK2 | protein_coding | tolerated(0.54) | benign(0.038) | TCGA-EY-A1GI-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ALG8 | SNV | Missense_Mutation | novel | c.916C>A | p.Leu306Ile | p.L306I | Q9BVK2 | protein_coding | tolerated(0.1) | probably_damaging(0.959) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |